TumorSight Risk
SimBioSys, Inc. · Decision date Sep 25, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for TumorSight Risk, submitted by SimBioSys, Inc., under 510(k) number K260023, with a decision date of September 25, 2026 and a receipt date of January 5, 2026. The device is a Class II software algorithm device analyzing digital images for cancer prognosis, regulation 21 CFR 864.3755, product code SHW, in the pathology specialty. The summary names ArteraAI Breast (K254115) as the legally marketed predicate. SESE means clearance, not PMA approval.
Per the indications for use, TumorSight Risk is a software-only device that combines age, race, cancer stage, nodal status and grade with DCE-MRI data to produce 5- and 10-year recurrence risks and a proprietary score, intended for adult women with HR+/HER2- Stage I-IIIA breast cancer. Its multi-tissue segmentation input is a validated output of TumorSight Viz (K251766). The record does not include the clinical validation results, performance metrics or the basis for the equivalence determination; those would need review of the linked decision summary.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Pathology
- Decision date
- Sep 25, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260023
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- SimBioSys, Inc.
- Product code
- SHW
- Decision code
- SESE
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pathology Software Algorithm Device Analyzing Digital Images For Breast Cancer Prognosis.
- Applicant
- SimBioSys, Inc.
- Product code
- SHW
- FDA device class
- 2
FDA decision timeline
K260023 received
Application receipt date recorded by FDA.
K260023 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
SimBioSys, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Chicago, IL
Sources and methodology
- Original FDA record: K260023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records